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Abstract
Cardiotoxicity induced by anti-cancer treatment has become a
significant threat as the number of cardiotoxic anti-cancer agents
is growing. Cancer patients are at an increased risk of contracting
coronavirus disease 2019 (COVID-19) because of immune sup-
pression caused by anti-cancer drugs and/or supportive treatment.
Deterioration in lung functions due to COVID-19 is responsible
for many cardiac events. The presence of COVID-19 and some of
its treatment modalities may increase the chance of cardiotoxicity
development in cancer patients receiving potentially cardiotoxic
agents. This review provides evidence-based information on the
cardiotoxicity risk in cancer patients clinically diagnosed with
COVID-19 who are receiving potentially cardiotoxic anti-cancer
agents. Proposed strategies relating to the management of this
patient cohorts are also discussed.
Introduction
Coronavirus disease 2019, more commonly referred to as
COVID-19, is a novel viral infection that has affected more than
185 countries worldwide.1 Following its declaration as a pandem-
ic by the World Health Organisation (WHO) in March 2020,
COVID-19 has been responsible for as many as 1,178,475 deaths
globally as of 30 October 2020.2 Severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) is the causative strain of
COVID-19. Common features among infected individuals include
fever, continuous cough and anosmia, however in more severe
cases complications such as pneumonia and acute respiratory fail-
ure have been reported.3 The continuous pressure of providing
patient care while maintaining strict infection control measures
has revealed and accumulated inadequacies in health-care systems
that make it harder to manage patients with acute respiratory dis-
tress syndrome (ARDS) as a result of COVID-19.4 Although the
majority of admitted patients were discharged without any serious
respiratory deteriorations, the number of patients requiring respi-
ratory support remains significant.5 In addition to the burden of
providing intensive respiratory intervention, there is some evi-
dence to suggest a relationship between COVID-19 and the devel-
opment of cardiotoxicity among some patients. Cardiovascular
complications among those diagnosed with COVID-19, such as
myocardial injury and cardiac dysfunction, have been attributed to
an increase in mortality in these acutely unwell patients.6,7 During
this pandemic, a subset of the population was defined as vulnera-
ble and in need of shielding. People living with cancer are one
example and have been shown to be more susceptible due to
immune suppression and overlapping toxicities. A study published
in The Lancet demonstrated the clinical outcomes of cancer
patients with COVID-19.8 Analysis of 928 patients showed high
30-day mortality of cancer patients with COVID-19 which was
associated with general or unique risk factors to cancer patients.
Older ager, male sex, smoking status, increased number of comor-
bidities, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 2 or higher, active cancer were the independent fac-
tors associated with increased 30-day mortality. Many anti-cancer
drugs play a role in the development of cardiotoxicity leading to
an increase in patient mortality.9-14 It is therefore not unreasonable
to assume that patients exposed to both COVID-19 and certain
anti-cancer agents are at a greatly increased risk of severe and
potentially life-threatening cardiotoxic complications. 
This review presents the evidence base of the cardiotoxicity
risk in cancer patients clinically diagnosed with COVID-19 along-
side proposed management strategies.
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Cardiovascular complications of COVID-19
The development of cardiac muscle injury can be attributed to
a number of factors or events. Adverse drug reactions, existing
comorbidities and other potential confounders such as age, smok-
ing and body mass index have a role to play.15 Interestingly, the
work by Ruane et al.16 has shown patients suffering from respira-
tory infections experience an increase in the occurrence of acute
cardiovascular abnormalities, namely myocardial infarction
(MI).16 Relative risk (RR) for MI was found to be elevated among
participants (17.0, 95% CI 13.2-21.8), even in those with milder
symptoms (13.5, CI 10.2-17.7). Similarly, in a recent study by
Wang et al.17 on 138 COVID-19 patients, cardiotoxicity developed
in nearly 24% of the sample cohort.17 This 24% comprised two
major cardiac pathologies including arrhythmia (16.7%, P<0.001)
and acute cardiac injury (7.2%, P<0.001). For patients admitted to
the intensive care unit, the incidence of arrhythmia (44.4%) and
acute cardiac injury (22.2%) was much higher. In a report by the
National Health Commission of China, 11.8% of the hospitalised
COVID-19 patients experienced a cardiac arrest or increase in car-
diac troponin I levels (cTnI), without any previous history of
underlying cardiovascular disease.18 A meta-analysis, including 30
studies and a total of 6389 COVID-19 patients, presented critical
cardiovascular complications.19 Arrhythmia (16.6%), acute cardiac
injury (15.7%) and heart failure (11.5%) were within the most
prevalent cardiovascular complications. Presence of previous car-
diac disease contributes to high mortality rates in COVID-19
patients. Although the development of cardiovascular toxicities is
sometimes associated with COVID-19, pre-existing cardiovascular
morbidities are also playing a role in the conditions of the patients
with COVID-19. According to a meta-analysis, heart failure was
associated with poor outcome in COVID-19 patients. Higher mor-
tality and hospitalisation were also more common in COVID-19
patients with heart failure than without.20 This underscores the
importance of management of patients with pre-existing heart dis-
ease during COVID-19. Beside the effects of heart failure during
COVID-19, endothelial dysfunction further increases the chance
of cardiotoxicity development in patients diagnosed with COVID-
19. The relationship between endothelial dysfunction and COVID-
19 associated coagulopathy and vascular inflammation has been
demonstrated.21 Viral infections in endothelial cells play a role in
endothelial activation and dysfunction. The presence of COVID-
19 relatively contributes to endothelial damage which can further
affect other organs such as the heart.22 In the presence of already
existed endothelial damage along with further diagnosis of
COVID-19, cardiotoxicity risk increases even more as COVID-19
also facilitates the endothelial damage.
Apart from effects of previous cardiac disease in COVID-19,
several case studies show development of multiple cardiovascular
events in patients without having any pre-existing cardiac disease.
The majority of COVID-19 patients do not develop serious cardio-
vascular side-effects whereas some patients exhibit multiple and
life-threatening cardiovascular conditions despite having no pre-
existing cardiovascular disease. The outcomes for these patients
were demonstrated with case reports. In a case study of a 37-year
old patient with COVID-19, myocardial injury was also reported.23
The electrocardiography (ECG) showed ST-segment elevation,
acute myocardial infarction and a significant increase in cardiac
markers [cTnI, brain natriuretic peptide (BNP), creatine kinase
isoenzyme (CK MB)]. Echocardiography also revealed ventricular
systolic dysfunction, showing 27% left ventricular ejection frac-
tion (LVEF). Elevated cTnI and N-terminal pro-brain natriuretic
peptide (NT-proBNP) levels, together with left ventricular dys-
function (LVEF: 32%), were present in another case study of a 63-
year old COVID-19 patient having no previous history of cardiac
disease.24 Aside from elevations in cardiac biomarkers and left
ventricular dysfunction, COVID-19 and the resulting pharma-
cotherapy have been attributed to other cardiovascular events, such
as QTc prolongation, as shown in Table 1.25,26
Cardiovascular effects of pharmacotherapies used
in COVID-19
To date, there is no finalised treatment strategy demonstrating
the exact therapeutic approach for COVID-19, however numerous
agents are being investigated for their therapeutic effect including
antiviral agents, corticosteroids, anti-inflammatory and immune-
based therapies and hydroxychloroquine. In this review, we
focused on cardiovascular effects of hydroxychloroquine, remde-
sivir, lopinavir/ritonavir, favipiravir, tocilizumab and dexametha-
sone. Both COVID-19 and its currently proposed treatment regi-
mens can contribute to cardiac abnormalities.27-30 Concurrent
administration of hydroxychloroquine and azithromycin (a
macrolide antibiotic) was a treatment strategy employed to tackle
COVID-19 in the beginning of pandemic.28 This combination was
believed to have a favourable effects on patient outcomes, however
they were associated with several clinically significant cardiovas-
cular adverse events including QTc prolongation, drug associated
torsades de pointes and sudden cardiac death.31-33 Evidence com-
paring the use of chloroquine or hydroxychloroquine alone versus
in combination with a macrolide antibiotic was provided by a large
scale multi-national project which included results for 96,032
patients hospitalised with COVID-19.34 Ventricular arrhythmias
were demonstrated to be the highest incidence in patients receiving
a combination of hydroxychloroquine together with a macrolide
antibiotic. This paper is retracted by The Lancet due to issuing an
expression of concern on 5 June 2020. Although hydroxychloro-
quine treatment was authorised to be used as emergency by Food
and Drug Administration (FDA), its authorisation withdrawn
because of the not effective results and the severe side effects.35
This regimen has now since been abandoned due to reports of no
added benefit and increased hospitalisation associated with its use.
Multiple research studies have reported on remdesivir, an
antiviral drug, to be effective in the treatment of adult COVID-19
patients.36-38 Clinical improvements were observed in hospitalised
patients. Even though its application showed improved patient out-
comes, cardiovascular side-effects such as severe hypotension
(8%), atrial fibrillation (6%), hypernatremia (6%) and multi-organ
dysfunction were observed.36 A case of cardiac arrest was demon-
strated in another study by Wang et al. in which the efficacy and
safety of remdesivir in COVID-19 patients in comparison with the
placebo group were tested.39 There is a need for increased amount
of clinical trials, especially multi-centre, demonstrating efficacy
and cardiac safety of remdesivir in COVID-19 patient populations.
There are ongoing trials investigating the therapeutic efficacy of
remdesivir in COVID-19 patients.40
                                                                                                                                Review
Table 1. Demonstration of several potential cardiovascular com-
plications in patients clinically diagnosed with COVID-19.
Cardiovascular complications          QTc prolongation
in COVID-19 patients                          Acute myocardial infarction 
                                                                 Left ventricular dysfunction
                                                                 Ventricular arrhythmia (ventricular
                                                                 tachycardia, ventricular fibrillation)
                                                                 Sudden cardiac death
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Lopinavir/ritonavir, a protease-inhibitor and antiretroviral
agent, is in use to check whether it is effective in the treatment of
COVID-19. Findings from a recent study showed some benefits of
lopinavir/ritonavir for secondary endpoints (i.e. shorter stay in
intensive care unit, duration of hospital stay, etc.).41 According to
a pharmacovigilance data in France, lopinavir/ritonavir was asso-
ciated with numerous cardiotoxicities in COVID-19 patients.42
These include ventricular arrhythmias, QTc prolongation, brady-
cardia and bundle branch block. Another case report demonstrated
the outcomes of the two patients received lopinavir/ritonavir for
human immunodeficiency virus (HIV).42 Both patients developed
severe cardiac arrhythmia within a month after the onset of drugs.
There are ongoing clinical trials testing the efficacy and safety of
lopinavir/ritonavir.43
Favipiravir is a synthetic prodrug and believed to be effective
in the treatment of COVID-19 due to its inhibitory effect of specif-
ic viral enzyme called RNA-dependent RNA polymerase (RdRp)
as Shannon et al. found SARS-CoV-2-RdRp complex is 10 times
more active than other viral RdRp known.44 Trials show favipiravir
to be effective in viral clearance, disease progression and relief of
cough and pyrexia.45,46 The cardiotoxicity incidence and safety
profile of favipiravir is relatively safe although there is one pub-
lished case study showing QTc interval prolongation in patient
who received favipiravir for Ebola virus.47 Use of other agents
such as vitamin C, dexamethasone, interferon-alpha, and mono-
clonal antibodies are under extensive research to find maximum
efficacy and safety in the treatment of COVID-19. These drugs are
also associated with several forms of cardiotoxicity either for
COVID-19 or other indications.48-51
Monoclonal antibody agents are one of the most popular ther-
apeutic strategies for the treatment of COVID-19. Trials with
tocilizumab, a recombinant monoclonal antibody, targeting the
interleukin (IL)-6 receptor has been shown to be an effective treat-
ment of COVID-19 with reduced mortality rates.52According to a
meta-analysis published before pandemic in non-COVID-19
patients, tocilizumab was found to be safe in terms of cardiovascu-
lar side-effects than other anti-rheumatoid agents.53 Tocilizumab is
believed to reduce the effects of COVID-19 on the heart because
of its ability to improve endothelial functions and reduce inflam-
mation and oxidative stress.54 Of particular relevance, the oxida-
tive stress theory is the proposed cardiotoxicity mechanism of
anthracycline chemotherapy.55 The most significant ongoing trial
testing the efficacy of tocilizumab and other agents such as dexam-
ethasone is the RECOVERY trial (clinicaltrials.gov no:
NCT04381936) with an aim to reach to estimated sample size of
20,000 patients.56
According to the published preliminary results of the RECOV-
ERY trial, dexamethasone, a glucocorticosteroid, was found to
improve 28-day mortality among hospitalised patients with
COVID-19 receiving respiratory support.57 National Health
Service (NHS) United Kingdom suggested the use of dexametha-
sone in critically ill patients with COVID-19 with a letter in accor-
dance with WHO suggestions.58 Although the exact cardiovascular
safety of dexamethasone in patients with COVID-19 was not
demonstrated in available literature, dexamethasone has a known
cardiovascular side-effect profile. The evidence of increased blood
pressure, tachycardia and other cardiac events were demonstrat-
ed.59-64
There are several agents under investigation for the treatment
of COVID-19. Some of these are known to trigger cardiovascular
events and some are relatively safe. However, the majority of phar-
macotherapies used in COVID-19 has at least one event of cardio-
vascular toxicity as explained above. Cardiac monitoring should
become an integral part of patient care, particularly in those with
other risk factors, such as exposure to anti-cancer agents, which in
turn may contribute to the risk of cardiotoxicity.
Cardiotoxicity of several anti-cancer drugs
Anthracycline and trastuzumab induced cardiotoxicity:
Increased risk when used as concurrent
Beyond the scope of the evidence provided by the various
cohort and case studies identifying cardiotoxicity associated with a
COVID-19 diagnosis and treatment alone, another significant sam-
ple of patients at risk includes those receiving anti-cancer therapies
that are also associated with cardiotoxicity.65 The cardiotoxicity of
anthracyclines, particularly doxorubicin and the human epidermal
growth factor receptor-2 (HER-2) antagonist trastuzumab, were
extensively studied in breast cancer patients, which found an
increase in risk as high as 34% when administered as combination
therapy.66-70 The type of cardiovascular event for these anti-cancer
treatments ranged from asymptomatic reduction in LVEF to sud-
den cardiac death.71,72 Doxorubicin and trastuzumab exhibit their
cardiotoxic effects via different pathways, hence they synergisti-
cally increase the risk of cardiovascular events when given concur-
rently. Doxorubicin is responsible for permanent cardiac muscle
death, whereas trastuzumab promotes reversible cardiomyocyte
dysfunction.73 In addition, doxorubicin cardiotoxicity is cumula-
tively dose-related, in contrast trastuzumab related myocardial
injury is dose-independent and can occur at any time. The risk of
cardiotoxicity with trastuzumab treatment alone is low but the dox-
orubicin-trastuzumab combinational regimen for HER-2 positive
breast cancer increases the risk of cardiotoxicity.(70) The mecha-
nism of cardiotoxicity for both agents intersect at HER-2 activity.
Doxorubicin binds to topoisomerase 2β in the heart causing DNA
double strands to break. This results in mitochondrial dysfunction
and free radical generation promoting cellular death.74 Myocardial
tissue has a regenerative mechanism through HER-2 upregulation,
however, inhibition of HER-2 with the addition of trastuzumab
inhibits the myocardial repair, which further increases the risk of
cardiotoxicity.75
Cardiotoxicity of new agents: tyrosine-kinase inhibitors
and immune check-point inhibitors
Tyrosine-kinase inhibitors
Dramatic improvements in cancer survival-rates have been
observed with the introduction of tyrosine-kinase inhibitors (TKIs)
and immune check-point inhibitors.76-81Although they are current-
ly employed to treat a range of cancers, their cardiotoxic side
effects restrict their overall usability.82,83 While anthracycline and
trastuzumab cardiotoxicity is related to changes in systolic func-
tion, TKI associated cardiotoxicities are more specifically related
with hypertension and ECG findings such as QTc prolongation,
bradycardia, tachycardia and T-wave inversion (e.g. atrial fibrilla-
tion, ventricular arrhythmia).84-89 The exact mechanism of TKI-
induced cardiotoxicity has not been completely identified. One
theory suggests vascular endothelial growth factor inhibition may
be a pathway through which the decrease in the amount of avail-
able nitric oxide (NO) results in an increasing abundance of reac-
tive oxygen species that contribute to various cardiovascular com-
plications.90 A meta-analysis of clinical trials using TKIs to target
the vascular endothelial growth factor receptor by Ghatalia et al.91
found an increased risk of QTc prolongation.91 Vantedanib, suni-
tinib, and pazopanib were the particular drugs of interest. QTc pro-










longation was observed in 4.41% (n=165/3737) and 0.25%
(n=7/2811) of the patients receiving TKI and non-TKI drugs,
respectively. Patients receiving TKIs were at higher risk of QTc
prolongation than patients receiving other drugs (RR=8.66, 95%
CI 4.92-15.2, P<0.001). In addition, the TKI cohort were at a
greater risk of high-grade QTc prolongation than non-TKI group
(RR=2.69, 95% CI 1.33-5.44, P=0.006). Other TKIs used in the
treatment of non-small cell lung cancer such as osimertinib, crizo-
tinib, ceritinib and brigatinib were also associated with several
types of cardiotoxicity including: QTc prolongation, hypertension,
bradycardia, etc.92-95
Immune check-point inhibitors
Newer therapeutic options, such as immune check-point
inhibitors, are also an effective treatment choice for several can-
cers. Chemotherapy, radiotherapy, and targeted treatments were
designed to directly inhibit cancer cell growth. Immune check-
point inhibitors utilise the immune system in order to recognise
cancer cells more effectively.96,97 Currently, there are eight
approved immune check-point inhibitors each with a different tar-
get receptor. Ipilimumab and tremelimumab target cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), pembrolizumab and
nivolumab target programmed cell death protein 1 (PD-1). The
remaining three immune check-point inhibitors, atezolizumab,
durvalumab and avelumab target programmed death-ligand 1 (PD-
L1) receptor. Ipilimumab, most commonly used in the treatment of
melanoma, has been associated with incidence of pericarditis,
myocardial fibrosis and cardiomyopathy.98-100 Furthermore, there
are case studies demonstrating the development of myocarditis
with nivolumab and pembrolizumab.101,102 Aside from myocardi-
tis, additional cardiovascular events, including ventricular arrhyth-
mia and Takotsubo-like cardiomyopathy, have been observed with
a number of immune check-point inhibitors.103 Given the rise in
availability of cardiotoxic anti-cancer agents, the need for collabo-
ration between cardiologists and oncologists has become even
more pertinent in the management of patient care. From this neces-
sity, a novel discipline of cardio-oncology has emerged.104 Cardio-
oncology is a field that not only seeks to provide patient care fol-
lowing the development of cardiovascular events, but also aims to
determine and establish risk factors, early diagnosis, cardiac
biomarkers, preventative and early treatment strategies as key prin-
ciples of patient management.
Pharmacotherapies used in COVID-19 and 
cardiotoxic anti-cancer drugs: common cardiac
side-effects
It is not unsurprising that those receiving treatment for cancer
are included in the high-risk group for COVID-19 given the effects
of immunosuppressant therapies and the impact of compromised
immune systems on contracting communicable diseases.105
However, despite this, the number of studies examining the inci-
dence of cancer in COVID-19 patients are limited. In a COVID-19
cohort study search, cancer comorbidity was reported in 10 studies
(Table 2).
Severe cases of COVID-19, pharmacotherapeutic approach
and receiving cardiotoxic anti-cancer treatment are all risk factors
for the development of cardiotoxicity. Therefore, cancer patients
receiving COVID-19 treatment should be monitored even more
closely given the potential synergistic risk posed by the numerous
factors that contribute to cardiotoxicity. Anti-cancer drug induced
cardiotoxicity can develop as an early- and/or late-onset. Some of
the cardiovascular events associated with anti-cancer treatments
can develop right after first cycle whereas some may develop years
after the termination of chemotherapy.
Early-onset cardiotoxicity
Hydroxychloroquine, azithromycin and some anti-viral agents
should be used cautiously among cancer patients whose anti-can-
cer regimen contains a TKI given the shared tendency for QTc pro-
longation.31-33,42,47 QTc prolongation is a predominantly early-
onset which may develop days to weeks after anti-cancer drug
administration. Concurrent use of agents may lead to a sudden
increase in QTc levels (>60 ms) resulting in value and to a level
>500 ms, which may further contribute to ventricular arrhythmias
and sudden cardiac death, especially in older populations.106,107 In
addition, COVID-19 patients treated with doxorubicin alone or in
combination with trastuzumab require additional monitoring as
both COVID-19, and some pharmacotherapies can increase the
risk of left ventricular dysfunction. A decrease in LVEF >10%
from baseline, associated with a drop to a level below 50% is an
accepted definition for left ventricular dysfunction.108,109 Left ven-
tricular dysfunction can be an early- or late- onset event.110
Therefore, stopping cancer treatment in patients receiving doxoru-
bicin and trastuzumab in order to commence COVID-19 therapy
                                                                                                                                Review
Table 2. Studies showing the incidence of cancer in patients clinically diagnosed with COVID-19.
Study                                                 Total COVID-19 cases (n)                       Total cancer cases (n)                          Cancer incidence (%)
Liang et al.112                                                                           1590                                                                             18                                                                             1.1
Zhang et al.113                                                                          1276                                                                             28                                                                             2.2
Guan et al.114                                                                           1099                                                                              8                                                                              0.7
Onder et al.115                                                                         355°                                                                             87                                                                            24.5
Shi et al.116                                                                                416                                                                               9                                                                              2.2
*Report from China117                                                         44672                                                                           107                                                                            0.5
Richardson et al.118                                                                5700                                                                            320                                                                              6
Nikpouraghdam et al.119                                                        2964                                                                             17                                                                             0.5
Cai et al.120                                                                                383                                                                               5                                                                              1.3
Lei et al.121                                                                                34#                                                                                5                                                                             14.7
Biran et al.139                                                                            764                                                                              98                                                                            12.8
Guaraldi et al.143                                                                      354                                                                              10                                                                             2.8
*Nationwide investigation from China; °all patients were dead; #all patients underwent to a surgical operation for another reason.
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may not always be preferable, particularly in the long term.
Although lower cumulative doses of doxorubicin are associated
with a lower incidence of cardiotoxicity development, cardiac
events resulting from trastuzumab are dose-independent and can
occur at any time, from days after first cycle to years after the final
dose of chemotherapy.111 As a result, the predictability of left ven-
tricular dysfunction is poor in patients receiving anthracyclines
and trastuzumab therapy. It is logical to assume that the potential
for the development of cardiotoxicity might strongly increase with
the presence of COVID-19 and concurrent administration of phar-
macotherapies.
Late-onset cardiotoxicity
There is not enough current evidence to definitely outline the
time-onset of cardiotoxicity. Anthracycline-induced cardiotoxicity
can be classified under three main types: acute, early-onset chronic
and late-onset chronic.112,113 Late-onset chronic progressive car-
diotoxicity generally develops following one year from the termi-
nation of anthracycline chemotherapy and can present as dilated
cardiomyopathy and arrhythmias.112 In a prospective study by
Tassan-Mangina et al.114 of adults receiving anthracycline therapy,
late-onset left ventricular function alteration was observed.114 The
LVEF of the patients was recorded at its lowest value (LVEF:
56±8%) 3.5 years after completion of anthracycline treatment
when compared with readings at baseline and 1-3 months after the
termination of chemotherapy, which reported LVEF values of
72±6% and 71±8%, respectively. In another study by Tsai et al.,115
the cardiac function was evaluated of long-term survivors of
Hodgkin’s lymphoma that received radiotherapy with or without
anthracycline chemotherapy.116 Echocardiography was performed
22±2 years after treatment cessation that confirmed myocardial
function alteration among both study groups, however it should be
noted that additional long-term negative left ventricular systolic
function effects were observed in the anthracycline treatment
group. When considering the needs of cancer patients with
COVID-19 and their available treatment options, it is essential to
discuss their treatment history, particularly given the potential car-
diotoxic impact of anthracyclines even decades after completion of
chemotherapy. Newly diagnosed COVID-19 patients who have a
history of cardiotoxic anti-cancer regimen may be more suscepti-
ble to develop new cardiotoxicities in the case of COVID-19 and
the administration of its potential pharmacotherapies.
Paediatric COVID-19 populations: overlapping
risks
Cardiotoxicity risk is significant and life-threatening for paedi-
atric populations. In developed countries, 5-years survival rate is
around 85% for paediatric cancer patients.116 Late chronic condi-
tions such as cardiovascular system abnormalities had increased
with prolonged life expectancy in children with cancer.117
According to a long term follow-up study, 27% of the childhood
cancer survivors exhibited abnormalities in cardiac dysfunction
which was associated with cumulative anthracycline dose, radia-
tion and young age at the time of diagnosis.118 The majority of chil-
dren with COVID-19 experience mild symptoms and do not
require hospitalisation. However, small number of children with
COVID-19 demonstrated the incidence of paediatric multisystem
inflammatory syndrome (PIMS) alike to Kawasaki disease which
affects multi-organ system including cardiovascular system.119
Paediatric patients who exhibited PIMS showed serious cardiac
events such as biventricular dysfunction, left ventricular systolic
impairment and coronary vessel abnormalities.119 The increased
incidence of hyperinflammatory events affecting multi-organ sys-
tem, has been proposed to overlap with COVID-19 diagnosis.
Although the reason remains unclear, it is pretty well known that
the multisystemic inflammation accelerates the incidence of car-
diovascular events as one of its proposed mechanisms.120 Children
with cancer should be closely and carefully monitored because
bidirectional risk of cardiotoxicity of both morbidities is severely
life-threatening. Children with cancer who receive cardiotoxic
anti-cancer agents and diagnosed with COVID-19 can be at higher
risk to cardiotoxicity than older patients due to higher incidence of
cardiovascular events associated with anti-cancer treatment and
severity of potential cardiac risks of multi-inflammation affecting
multi-organ system during COVID-19.
Thoracic radiotherapy
Administration of thoracic radiation in addition to anti-cancer
treatment is a frequent strategy used to target a number of cancers.
As single therapy, in combination or post- chemotherapy radiother-
apy can result in several pulmonary and cardiovascular complica-
tions.121 Fibrotic changes in cardiac valves, coronary artery dis-
ease, and damage to the peri- and myocardium have all been asso-
ciated with radiation therapy.122 Thoracic radiation can also cause
permanent damage to pulmonary tissue resulting in respiratory
dysfunction in up to 30% of patients.123 Changes in the morpholo-
gy of respiratory and cardiac tissue are associated with severe
COVID-19 infections, as well as treatments such as hydroxy-
chloroquine, and therefore may further exacerbate the burden of
pulmonary fibrosis experienced by patients receiving thoracic radi-
ation. Concurrent use of thoracic radiotherapy together with car-
diotoxic anti-cancer drugs in COVID-19 cancer patients will
potentially increase patient mortality as a result of the augmented
risk to this patient group, therefore careful consideration should be
take prior to the initiation of treatment, especially in those with
breast and lung cancers (Figure 1).
Hypertension
Cardiovascular risk factors in cancer patients such as age, renal
failure, previous cardiac disease and hypertension might increase
the chance of cardiotoxicity development in patients suffering both
from cancer and COVID-19 (Figure 2).124 According to European
Society of Cardiology (ESC), hypertension is a cardiovascular risk
factor for cancer patients receiving treatment with anthracy-
clines.124 Incidentally, the presence of hypertension is believed to
increase the severity of COVID-19 due to the administration of
antihypertensives such as angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). The
proposed linked to an increased susceptibility COVID-19 is theo-
rised as a result of upregulation of angiotensin converting enzyme-
2 (ACE-2) expression in lungs with ACEI and ARB therapy.125-127
ACE-2 facilitates viral transmission into cells which may poten-
tially increase the development of ARDS.128 However, ESC and
International Society of Hypertension (ISH) announced statements
advocating not to discontinue ACEI/ARB treatment.129,130 Their
statement follows a recent meta-analysis that describes the overall
benefit for continued ACEI/ARB treatment in COVID-19 patients,
which found an overall reduction in severity and mortality.131 The
authors note that individual factors such as ACE-2 polymorphism
however still require further evaluation to help stratify patient risk









on a case by case basis. ACE-2 is not only expressed in lungs but
also widely presented in the myocardium which may shed some
light on the underlying mechanism contributing to the high inci-
dence of cardiotoxicity in patients with hypertension. However,
further investigation is warranted given the overall paucity of evi-
dence and disagreement across the current literature. Taking the
current findings into account, management of patients presenting
with cancer, COVID-19 and hypertension should be comprehen-
sive in its approach to monitoring and assessing patients on a case
by case basis while we await further clarification on best practice
for this cohort.
Management of COVID-19 in patients living with
cancer
Finding the cardiovascular-associated links between anti-can-
cer drugs, COVID-19 and its proposed pharmacotherapies is pos-
sible by comprehensive evaluation of drug history at the baseline.
Importance of baseline and serial cardiovascular 
evaluation
Baseline cardiovascular assessments are an integral part of
patient care for those with cancer and receiving cardiotoxic anti-
cancer agents.131 A comprehensive baseline evaluation should
include ECG, echocardiography, biochemical marker testing,
physical cardiology check and a comprehensive evaluation of drug
history. Each potentially cardiotoxic anti-cancer treatment were
identified with different forms of cardiotoxicity with different
onsets. The use of biochemical markers in early diagnosis/predic-
tion of cardiotoxicity in cancer patients is controversial in the lit-
erature and their role has not become clear yet together with con-
siderable amount of studies could not show any predictive value.
The use of biochemical markers can be misleading in patients with
COVID-19 and cancer as biomarkers may rise due to other rea-
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Figure 2. Factors that increase cardiotoxicity development risk in COVID-19 cancer patients receiving cardiotoxic anti-cancer treat-
ments.
Figure 1. Demonstration of several factors (i.e. pulmonary function alteration due to COVID-19, pharmacotherapies used in COVID-
19, administration of potentially cardiotoxic agents and thoracic radiotherapy-induced pulmonary fibrosis) inducing cardiovascular
toxicity development.










son(s) during the viral infections. Therefore it is hard to attribute
the marker elevation and cardiovascular events to anti-cancer ther-
apy or to COVID-19.132 The baseline evaluation provides an
opportunity for comparison of future results with pre-chemothera-
py data. Serial monitoring is another key practice of cardio-oncol-
ogy. Serial ECGs and echocardiography assessments pave the way
for detecting potential cardiovascular events as early as possible.
In addition to routine assessments, patients should be evaluated at
the time of and serially following a clinical diagnosis of COVID-
19 (Figure 3). A respiratory assessment should also be an integral
part of patient management given the correlation between the
severity of respiratory infection and the development of cardiotox-
icity.16 Under normal circumstances, cardiologists, oncologists,
and nurses make up the bulk of the cardio-oncology team.133,134
For severe COVID-19 cases, in which there is respiratory function
alteration, intervention from respiratory teams is vital in support-
ing the role of cardio-oncology. This also extends to pharmacists
who can offer critical insights on medicines management includ-
ing: safety and efficacy of prescribed treatments and doses, com-
prehensive drug history and medicines reconciliation and the mon-
itoring of treatment response and adverse effects, particularly car-
dio-toxicity.
Cardiovascular toxicity guidelines for cancer patients:
minor modifications for COVID-19
There are existing cardiovascular toxicity guidelines for cancer
patients.124,135,136 The wide spectrum of guidance was created with
the aim to counteract the risk of cardiotoxicity among this patient
group. Aside from the principles and considerations discussed in
this article, the guidelines encourage the uptake of consistent base-
line and serial assessments including the use of the same imaging
tools throughout the evaluation process. Echocardiography might
not provide similar or reliable readings when different devices are
used, which may lead to misinterpretation of results.137 Myocardial
                                Review
Figure 3. Outlines possible step by step management of cancer patients receiving cardiotoxic anti-cancer agents clinically diagnosed
with COVID-19.










strain imaging is a new approach that has been found to be more
sensitive than LVEF for detecting subclinical left ventricular sys-
tolic dysfunction.138 However, validation of biomarkers has not
been definitively confirmed yet. To date, only early diagnosis of
left ventricular impairment has been studied. Therefore, the only
recommendation can be made for early diagnosis of left ventricular
dysfunction and no other ECG related abnormalities such as QTc
prolongation. According to the guidelines, the use of intensity
modulated and 3D conformal radiotherapy are preferred tech-
niques for thoracic radiotherapy as they are associated with a
reduced risk of early or late cardiovascular toxicity development.
Prophylactic use of ACEIs or ARBs and/or beta blockers and/or
statins to reduce the risk of cardiotoxicity is another highlighted
recommendation within the guidelines that requires individual
patient assessment. As there is still continuing debate related to
COVID-19 and anti-hypertensives, the patients should be moni-
tored serially and closely. The use of ACEI can potentially be used
to reduce the chance of occurrence of cardiotoxicity but with cau-
tious and close monitoring in COVID-19 patients until the topic is
clear. It should also be clearly known that these agents are not
interchangeable, and their preventive activity does not support
asymptomatic patients.
Conclusions
COVID-19 has taken the global centre stage in recent months;
however, it is important to consider the patients beyond the disease
itself and the increased exposure to risk that they may face in light
of this current pandemic. Both cancer and COVID-19, as well as
their respective therapy options are known to contribute to car-
diotoxicity. The long-term cardiac health impact of a previous
COVID-19 diagnosis is yet to be understood. For these reasons, a
holistic approach to management is essential in supporting cancer
patients to achieve the most positive outcomes while navigating
the challenge of patient therapy. It is imperative to recognise the
overlap in symptoms and treatment side effects associated with
both COVID-19 and cancer treatment. In practice and whilst
awaiting further evidence, this would come down to understanding
the nature of symptoms and toxicity in addition to frequency
alongside a holistic clinical history taking including comprehen-
sive screening of drug history at the baseline. Education and train-
ing should take place in this regard in order to allow early recog-
nition and timely management. Furthermore, close monitoring and
an enhanced multi-disciplinary team are essential in providing
optimal care for these patients. A proactive approach in the evalu-
ation of emerging evidence, guidelines and patient case studies
will provide the best foundation for effective decision making to
ensure patients receive the full benefit from their treatment whilst
avoiding cardiotoxicity.
References
1. Dong E, Du H, Gardner L. An interactive web-based dashboard
to track COVID-19 in real time. Lancet Infect Dis
2020;20:533-4.
2. World Health Organization (WHO). Coronavirus disease dash-
board; 2020. Available from: https://COVID19.who.int/
Accessed: 30 October 2020.
3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak asso-
ciated with a new coronavirus of probable bat origin. Nature
2020;579:270-3. 
4. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next?.
Lancet 2020;395:1225-8. 
5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumo-
nia in Wuhan, China: a descriptive study. Lancet
2020;395:507-13. 
6. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and car-
diovascular disease. Circulation 2020;141:1648-55. 
7. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of
fatal outcomes of patients with coronavirus disease 2019
COVID-19. JAMA Cardiol 2020;5:1-8. 
8. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of
COVID-19 on patients with cancer CCC19.: a cohort study.
Lancet 2020;395:1907-18. 
9. Santoni M, Guerra F, Conti A, et al. Incidence and risk of car-
diotoxicity in cancer patients treated with targeted therapies.
Cancer Treat Rev 2017;59:123-31. 
10. Lenneman CG, Sawyer DB. Cardio-oncology: an update on
cardiotoxicity of cancer-related treatment. Circ Res
2016;118:1008-20.
11. Colombo A, Cardinale D. Using cardiac biomarkers and treat-
ing cardiotoxicity in cancer. Future Cardiol 2013;9:105-18.
12. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL.
Cardiotoxicity in cancer patients treated with 5-fluorouracil or
capecitabine: a systematic review of incidence, manifestations
and predisposing factors. Cancer Treat Rev 2013;39:974-84. 
13. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction
in patients receiving cardiotoxic cancer therapies are clini-
cians responding optimally?. J Am Coll Cardiol
2010;56:1644-50.
14. Colombo A, Meroni CA, Cipolla CM, Cardinale D. Managing
cardiotoxicity of chemotherapy. Curr Treat Options
Cardiovasc Med 2013;15:410-24. 
15. Pacher P, Kecskemeti V. Cardiovascular side effects of new
antidepressants and antipsychotics: new drugs, old concerns?.
Curr Pharm Des 2004;10:2463-75. 
16. Ruane L, Buckley T, Hoo SYS, Hansen PS, et al. Triggering of
acute myocardial infarction by respiratory infection. Intern
Med J 2017;47:522-29.
17. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hos-
pitalized patients with 2019 novel coronavirus-infected pneu-
monia in Wuhan, China. JAMA 2020;323:1061-9. 
18. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the car-
diovascular system. Nat Rev Cardiol 2020;17:259-60.
19. Vakili K, Fathi M, Pezeshgi A, et al. Critical complications of
COVID-19: A descriptive meta-analysis study. Rev
Cardiovasc Med 2020;21:433-42. 
20. Yonas E, Alwi I, Pranata R, et al. Effect of heart failure on the
outcome of COVID-19 - A meta analysis and systematic
review. Am J Emerg Med 2020;S0735-675720.30602-1. 
21. Zhang J, Tecson KM, McCullough PA. Endothelial dysfunc-
tion contributes to COVID-19-associated vascular inflamma-
tion and coagulopathy. Rev Cardiovasc Med 2020;21:315-9. 
22. Zuchi C, Tritto I, Carluccio E, et al. Role of endothelial dys-
function in heart failure. Heart Fail Rev 2020;25:21-30.
23. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocardi-
tis saved with glucocorticoid and human immunoglobulin.
Eur Heart J 2020;ehaa190.
24. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 com-
plicated with fulminant myocarditis: a case report and
insights. Infection 2020;1-5.
25. O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe
QTc prolongation in patient with systemic lupus erythemato-
sus due to hydroxychloroquine. Case Rep Cardiol
                                          [Oncology Reviews 2021; 15:510]                                                            [page 29]









[page 30]                                                             [Oncology Reviews 2021; 15:510]                                          
2016;2016:4626279.
26. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet 2020;395:1054-
62. 
27. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolon-
gation and torsade de pointes in patients with COVID-19
treated with hydroxychloroquine/azithromycin. Heart Rhythm
2020;S1547-5271:30435-5.
28. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and
azithromycin as a treatment of COVID-19: results of an open-
label non-randomized clinical trial. Int J Antimicrob Agents
2020;56:105949. 
29. Fresse A, Viard D, Romani S, et al. Spontaneous reported car-
diotoxicity induced by lopinavir/ritonavir in COVID-19. An
alleged past-resolved problem. Int J Cardiol 2020 16:S0167-
527320.33981-4. 
30. Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral
drug remdesivir: An update. Biomed Pharmacother
2020;130:110532.
31. Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardio-
vascular presentations of COVID-19. Circulation
2020;141:1930-6. 
32. Huang BH, Wu CH, Hsia CP, Chen CY. Azithromycin-induced
torsade de pointes. Pacing Clin Electrophysiol 2007;30:1579-
82.
33. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a
cause of QT-interval prolongation and torsade de pointes in
the absence of other known precipitating factors. J Interv Card
Electrophysiol 2007;18:243-6.
34. Mehra MR, Ruschitzka F, Patel AN. Retraction-
Hydroxychloroquine or chloroquine with or without a
macrolide for treatment of COVID-19: a multinational reg-
istry analysis. Lancet 2020;395:1820.
35. Skipper CP, Pastick KA, Engen NW, et al.
Hydroxychloroquine in nonhospitalized adults with early
COVID-19: a randomized trial. Ann Intern Med
2020;173:623-31.
36. Grein J, Ohmagari N, Shin D, et al. Compassionate use of
remdesivir for patients with severe COVID-19. N Engl J Med
2020;382:2327-36.
37. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a
possible therapeutic option for the COVID-19. Travel Med
Infect Dis 2020;34:101615. 
38. Olender SA, Perez KK, Go AS, et al. Remdesivir for severe
COVID-19 versus a cohort receiving standard of care. Clin
Infect Dis 2020;ciaa1041.
39. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with
severe COVID-19: a randomised, double-blind, placebo-con-
trolled, multicentre trial. Lancet 2020;395:1569-78. 
40. United States National Library of Medicine. Remdesivir
COVID-19 trials; 2020. Available from: https://www.clinical-
trials.gov/ct2/results?cond=COVID19&term=remdesivir&cnt
ry=&state=&city=&dist= Accessed: 20 November 2020.
41. Cao B, Wang Y, Wen D, et al. A Trial of lopinavir-ritonavir in
adults hospitalized with severe COVID-19. N Engl J Med
2020;382:1787-99.
42. Chaubey SK, Sinha AK, Phillips E, et al. Transient cardiac
arrhythmias related to lopinavir/ritonavir in two patients with
HIV infection. Sex Health 2009;6:254-7. 
43. United States National Library of Medicine. Lopinavir/riton-
avir COVID-19 trials; 2020. Available from:
https://www.clinicaltrials.gov/ct2/results?cond=COVID19&t
erm=Lopinavir%2Fritonavir&cntry=&state=&city=&dist=
Accessed: 20 November 2020.
44. Shannon A, Selisko B, Le N, et al. Favipiravir strikes the
SARS-CoV-2 at its Achilles heel, the RNA polymerase.
Preprint. bioRxiv 2020;2020.05.15.098731. 
45. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for
COVID-19: a randomized clinical trial. MedRxiv 2020 [Epub
ahead of print]. https://doi.org/10.1101/2020.03.17.20037432.
46. Cai Q, Yang M, Liu D, et al. Experimental treatment with
favipiravir for COVID-19: an open-label control study.
Engine Beijing 2020 [Epub ahead of print].
https://doi:10.1016/j.eng.2020.03.007.
47. Chinello P, Petrosillo N, Pittalis S, et al. QTc interval prolon-
gation during favipiravir therapy in an Ebolavirus-infected
patient. PLoS Negl Trop Dis 2017;11:e0006034. 
48. de Salvi Guimarães F, de Moraes WM, Bozi LH, et al.
Dexamethasone-induced cardiac deterioration is associated
with both calcium handling abnormalities and calcineurin sig-
naling pathway activation. Mol Cell Biochem 2017;424:87-
98. 
49. Bacchiega BC, Bacchiega AB, Usnayo MJ, et al. Interleukin 6
inhibition and coronary artery disease in a high-risk popula-
tion: a prospective community-based clinical study. J Am
Heart Assoc 2017;6:e005038.
50. Lee DH, Folsom AR, Harnack L, et al. Does supplemental vita-
min C increase cardiovascular disease risk in women with dia-
betes? Am J Clin Nutr 2004;80:1194-200. 
51. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and
clinical therapies on coronavirus disease 2019 COVID-19.
outbreak - an update on the status. Mil Med Res 2020;7:11.
52. Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with
COVID-19 in the intensive care unit: a multicentre observa-
tional study. Lancet Rheumatol 2020;2:e603-12. 
53. Castagné B, Viprey M, Martin J, et al. Cardiovascular safety of
tocilizumab: A systematic review and network meta-analysis.
PLoS One 2019;14:e0220178.
54. Ikonomidis I, Pavlidis G, Katsimbri P, et al. Tocilizumab
improves oxidative stress and endothelial glycocalyx: A
mechanism that may explain the effects of biological treat-
ment on COVID-19. Food Chem Toxicol 2020;145:111694.
55. Sala V, Della Sala A, Hirsch E, Ghigo A. Signaling pathways
underlying anthracycline cardiotoxicity. Antioxid Redox
Signal 2020;32:1098-114.
56. United States National Library of Medicine. Randomised
Evaluation of COVID-19 Therapy RECOVERY. trial
NCT04381936; 2020. Available from: https://clinicaltrials.
gov/ct2/show/NCT04381936?cond=NCT04381936&draw=2
&rank=1 Accessed: 16 November 2020.
57. RECOVERY Collaborative Group; Horby P, Lim WS, et al.
Dexamethasone in hospitalized patients with COVID-19 -
preliminary report. N Engl J Med 2020;NEJMoa2021436. 
58. National Health Service NHS. England. COVID-19 therapy:
corticosteroids including dexamethasone and hydrocortisone;
2020. Available from:  https://www.england.nhs.uk/publica-
tion/COVID-19-therapy-corticosteroids-including-dexam-
ethasone-and-hydrocortisone/ Accessed: 17 November 2020.
59. Bernal-Mizrachi C, Weng S, Feng C, et al. Dexamethasone
induction of hypertension and diabetes is PPAR-alpha depen-
dent in LDL receptor-null mice. Nat Med 2003;9:1069-75. 
60. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they
damage the cardiovascular system? Postgrad Med J
1994;70:863-70.
61. Sicard RE, Werner JC. Biochemical correlates of dexametha-
sone-induced relative cardiomegaly in neonatal rats. In vivo
1995;9:75-9.










62. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension.
Pediatr Nephrol 2012;27:1059-66. 
63. Roy SG, De P, Mukherjee D, Chander V, et al. Excess of glu-
cocorticoid induces cardiac dysfunction via activating
angiotensin II pathway. Cell Physiol Biochem 2009;24:1-10. 
64. Souverein PC, Berard A, Van Staa TP, et al. Use of oral gluco-
corticoids and risk of cardiovascular and cerebrovascular dis-
ease in a population based case-control study. Heart
2004;90:859-65.
65. Shaikh AY, Shih JA. Chemotherapy-induced cardiotoxicity.
Curr Heart Fail Rep 2012;9:117-27. 
66. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemother-
apy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med
2001;344:783-92.
67. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-
related cardiotoxicity: calling into question the concept of
reversibility. J Clin Oncol 2007;25:3525-33. 
68. Yeh ET, Bickford CL. Cardiovascular complications of cancer
therapy: incidence, pathogenesis, diagnosis, and management.
J Am Coll Cardiol 2009;53:2231-47. 
69. Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced
cardiomyopathy: not as benign as it looks? A retrospective
study. J Card Fail 2009;15:651-7. 
70. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in
the trastuzumab clinical trials experience. J Clin Oncol
2002;20:1215-21.
71. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tol-
erability of trastuzumab in metastatic breast cancer: the M.D.
Anderson Cancer Center experience. J Clin Oncol
2006;24:4107-15.
72. Calistri L, Cordopatri C, Nardi C, et al. Sudden cardiac death
in a patient with advanced hepatocellular carcinoma with
good response to sorafenib treatment: A case report with liter-
ature analysis. Mol Clin Oncol 2017;6:389-96.
73. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac
dysfunction: time to recognize a new entity. J Clin Oncol
2005;23:2900-2. 
74. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced car-
diotoxicity: challenges and opportunities. J Am Coll Cardiol
2014;64:938-45.
75. Ewer MS, Ewer SM. Troponin I provides insight into car-
diotoxicity and the anthracycline-trastuzumab interaction. J
Clin Oncol 2010;28:3901-4.
76. Valerio L, Pieruzzi L, Giani C, et al. Targeted therapy in thyroid
cancer: state of the art. Clin Oncol R Coll Radiol
2017;29:316-24.
77. Porta C, Procopio G, Cartenì G, et al. Sequential use of
sorafenib and sunitinib in advanced renal-cell carcinoma
RCC: an Italian multicentre retrospective analysis of 189
patient cases. BJU Int 2011;108:E250-E7.
78. Ellis PM, Coakley N, Feld R, et al. Use of the epidermal
growth factor receptor inhibitors gefitinib, erlotinib, afatinib,
dacomitinib, and icotinib in the treatment of non-small-cell
lung cancer: a systematic review. Curr Oncol 2015;22:e183-
e215.
79. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010;363:711-23. 
80. Robert C, Long GV, Brady B, et al. Nivolumab in previously
untreated melanoma without BRAF mutation. N Engl J Med
2015;372:320-30.
81. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and
long-term safety of nivolumab anti-programmed death 1 anti-
body, BMS-936558, ONO-4538. in patients with previously
treated advanced non-small-cell lung cancer. J Clin Oncol
2015;33:2004-12.
82. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity
induced by tyrosine kinase inhibitors. Acta Oncol
2009;48:964-70.
83. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated
with CTLA4 and PD1 blocking immunotherapy. J
Immunother Cancer 2016;4:50.
84. Kloth JS, Pagani A, Verboom MC, et al. Incidence and rele-
vance of QTc-interval prolongation caused by tyrosine kinase
inhibitors. Br J Cancer 2015;112:1011-6.
85. Asnani A, Manning A, Mansour M, et al. Management of atrial
fibrillation in patients taking targeted cancer therapies.
Cardiooncology 2017;3:2.
86. Teng AE, Share M, Hsu JJ, et al. Torsades de pointes with pseu-
do-T wave alternans during rociletinib therapy: A novel man-
ifestation of a rare side effect. Heart Rhythm Case Rep
2018;4:490-3.
87. Agarwal M, Thareja N, Benjamin M, et al. Tyrosine kinase
inhibitor-induced hypertension. Curr Oncol Rep 2018;20:65.
88. Minoia C, Giannoccaro M, Iacobazzi A, et al. Antineoplastic
drug-induced bradyarrhythmias. Expert Opin Drug Saf
2012;11:739-51. 
89. Spechbach H, Morel P, Lorenzini KI, et al. Reversible ventric-
ular arrythmia induced by dasatinib. Clin Case Rep
2013;1:20-5.
90. Sueta D, Suyama K, Sueta A, et al. Lenvatinib, an oral multi-
kinases inhibitor, -associated hypertension: potential role of
vascular endothelial dysfunction. Atherosclerosis
2017;260:116-20.
91. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolon-
gation with vascular endothelial growth factor receptor tyro-
sine kinase inhibitors. Br J Cancer 2015;112:296-305. 
92. Watanabe H, Ichihara E, Kano H, et al. Congestive heart failure
during osimertinib treatment for epidermal growth factor
receptor EGFR(-mutant non-small cell lung cancer NSCLC).
Intern Med 2017;56:2195-7. 
93. Maurea N, Spallarossa P, Cadeddu C, et al. A recommended
practical approach to the management of target therapy and
angiogenesis inhibitors cardiotoxicity: an opinion paper of the
working group on drug cardiotoxicity and cardioprotection,
Italian Society of Cardiology. J Cardiovasc Med Hagerstown
2016;17:S93-S104.
94. Tartarone A, Gallucci G, Lazzari C, et al. Crizotinib-induced
cardiotoxicity: the importance of a proactive monitoring and
management. Future Oncol 2015;11:2043-8. 
95. Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and
safety of brigatinib in ALK-rearranged non-small-cell lung
cancer and other malignancies: a single-arm, open-label,
phase 1/2 trial. Lancet Oncol 2016;17:1683-96.
96. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase
inhibitors and implications for therapeutic strategies. Clin
Cancer Res 2014;20:2249-56.
97. Wolchok JD, Hodi FS, Weber JS, et al. Development of ipili-
mumab: a novel immunotherapeutic approach for the treat-
ment of advanced melanoma. Ann N Y Acad Sci 2013;1291:1-
13.
98. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor
control: an analysis of rare side effects of anti-CTLA-4 thera-
py in metastatic melanoma from the ipilimumab network.
PLoS One 2013;8:e53745.
99. Yun S, Vincelette ND, Mansour I, et al. Late onset ipilimumab-
induced pericarditis and pericardial effusion: a rare but life
                                          [Oncology Reviews 2021; 15:510]                                                            [page 31]










[page 32]                                                             [Oncology Reviews 2021; 15:510]                                          
threatening complication. Case Rep Oncol Med
2015;2015:794842.
100. Geisler BP, Raad RA, Esaian D, et al. Apical ballooning and
cardiomyopathy in a melanoma patient treated with ipilimum-
ab: a case of takotsubo-like syndrome. J Immunother Cancer
2015;3:4.
101. Inayat F, Masab M, Gupta S, Ullah W. New drugs and new
toxicities: pembrolizumab-induced myocarditis. BMJ Case
Rep 2018;2018:bcr2017223252.
102. Semper H, Muehlberg F, Schulz-Menger J, et al. Drug-
induced myocarditis after nivolumab treatment in a patient
with PDL1-negative squamous cell carcinoma of the lung.
Lung Cancer 2016;99:117-9.
103. Yang S, Asnani A. Cardiotoxicities associated with immune
checkpoint inhibitors. Curr Probl Cancer 2018;42:422-32.
104. Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-
Oncology Services: rationale, organization, and implementa-
tion. Eur Heart J 2019;40:1756-63. 
105. Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical
approach to the management of cancer patients during the
novel coronavirus disease 2019 (COVID-19) pandemic: An
International Collaborative Group. Oncologist 2020;25:e936-
e45. 
106. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc
interval and risk of sudden cardiac death in a population of
older adults. J Am Coll Cardiol 2006;47:362-7. 
107. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval
prolongation among cancer patients treated with vandetanib: a
systematic review and meta-analysis. PLoS One
2012;7:e30353. 
108. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-
associated cardiac adverse effects in the herceptin adjuvant
trial. J Clin Oncol 2007;25:3859-65. 
109. Nousiainen, T, Jantunen E, Vanninen E, Hartikainen J. Early
decline in left ventricular ejection fraction predicts doxoru-
bicin cardiotoxicity in lymphoma patients. Br J Cancer
2002;86:1697-700. 
110. Kumar S, Marfatia R, Tannenbaum S, et al. Doxorubicin-
induced cardiomyopathy 17 years after chemotherapy. Tex
Heart Inst J 2012;39:424-7.
111. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments.
Nat Rev Cardiol 2015;12:547-58.
112. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associat-
ed cardiotoxicity in survivors of childhood cancer. Heart
2008;94:525-33.
113. Wojtacki J, Lewicka-Nowak E, Leśniewski-Kmak K.
Anthracycline-induced cardiotoxicity: clinical course, risk
factors, pathogenesis, detection and prevention—review of
the literature. Med Sci Monit 2000;6:411-20.
114. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue
Doppler imaging and conventional echocardiography after
anthracycline treatment in adults: early and late alterations of
left ventricular function during a prospective study. Eur J
Echocardiogr 2006;7:141-6. 
115. Tsai HR, Gjesdal O, Wethal T, et al. Left ventricular function
assessed by two-dimensional speckle tracking echocardiogra-
phy in long-term survivors of Hodgkin’s lymphoma treated by
mediastinal radiotherapy with or without anthracycline thera-
py. Am J Cardiol 2011;107:472-7. 
116. Doctor-approved patient information from American Society
of Clinical Oncology (ASCO). Childhood Cancer: Statistics;
2020. Available from: https://www.cancer.net/cancer-
types/childhood-cancer/statistics Accessed: 17 November
2020.
117. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardio-
vascular toxicity in children, adolescents, and young adults
who receive cancer therapy: pathophysiology, course, moni-
toring, management, prevention, and research directions: a
scientific statement from the American Heart Association.
Circulation 2013;128:1927-95. 
118. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac
function in 5-year survivors of childhood cancer: a long-term
follow-up study. Arch Intern Med 2010;170:1247-55. 
119. Riphagen S, Gomez X, Gonzalez-Martinez C, et al.
Hyperinflammatory shock in children during COVID-19 pan-
demic. Lancet 2020;395:1607-8. 
120. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19:
immunity, inflammation and intervention. Nat Rev Immunol
2020;20:363-74.
121. Domercant J, Polin N, Jahangir E. Cardio-oncology: a
focused review of anthracycline-, human epidermal growth
factor receptor 2 inhibitor-, and radiation-induced cardiotoxi-
city and management. Ochsner J 2016;16:250-6.
122. Hong RA, Iimura T, Sumida KN, Eager RM. Cardio-oncolo-
gy/onco-cardiology. Clin Cardiol 2010;33:733-7.
123. He Y, Thummuri D, Zheng G, et al. Cellular senescence and
radiation-induced pulmonary fibrosis. Transl Res
2019;209:14-21.
124. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016
ESC Position Paper on cancer treatments and cardiovascular
toxicity developed under the auspices of the ESC Committee
for Practice Guidelines: The Task Force for cancer treatments
and cardiovascular toxicity of the European Society of
Cardiology ESC. Eur Heart J 2016;37:2768-801. 
125. Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme inhibition and angiotensin II
receptor blockers on cardiac angiotensin-converting enzyme
2. Circulation 2005;111:2605-10. 
126. Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone
and eprosartan on cardiac remodeling and angiotensin-con-
verting enzyme isoforms in rats with experimental heart fail-
ure. Am J Physiol Heart Circ Physiol 2005;289:1351-8.
127. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of
angiotensin-converting enzyme 2 after myocardial infarction
by blockade of angiotensin II receptors. Hypertension
2004;43:970-6. 
128. Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system
blockers and the COVID-19 pandemic: at present there is no
evidence to abandon renin-angiotensin system blockers.
Hypertension 2020;75:1382-5.
129. European Society of Cardiology (ESC). Position statement of
the ESC Council on hypertension on ACE-inhibitors and





130. International Society of Hypertension ISH.. A statement from
the International Society of Hypertension on COVID-19;
2020. Available from: https://ish-world.com/news/a/A-state-
ment-from-the-International-Society-of-Hypertension-on-
COVID-19/ Accessed: 5 August 2020.
131. Grover A, Oberoi M. A systematic review and meta-analysis
to evaluate the clinical outcomes in COVID-19 patients on
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers. Eur Heart J Cardiovasc Pharmacother
2020;pvaa064. 
132. European Society of Cardiology ESC. Council of Cardio-









Oncology. Routine cardiotoxicity echo screening for





133. Barros-Gomes S, Herrmann J, Mulvagh SL, et al. Rationale
for setting up a cardio-oncology unit: our experience at Mayo
Clinic. Cardio-Oncology 2016;2:5. 
134. Fradley MG, Brown AC, Shields B, et al. Developing a com-
prehensive cardio-oncology program at a Cancer Institute:
The Moffitt Cancer Center Experience. Oncol Rev
2017;11:340. 
135. Virani SA, Dent S, Brezden-Masley C, et al. Canadian
Cardiovascular Society Guidelines for Evaluation and
Management of Cardiovascular Complications of Cancer
Therapy. Can J Cardiol 2016;32:831-41.
136. López-Fernández T, García AM, Beltrán AS, et al. Cardio-
Onco-Hematology in Clinical Practice. Position Paper and
Recommendations. Rev Esp Cardiol Engl (Ed). 2017;70:474-
86. 
137. Jenkins C, Bricknell K, Hanekom L, Marwick TH.
Reproducibility and accuracy of echocardiographic measure-
ments of left ventricular parameters using real-time three-
dimensional echocardiography. J Am Coll Cardiol 2004;44:
878-86. 
138. Kalam K, Otahal P, Marwick TH. Prognostic implications of
global LV dysfunction: a systematic review and meta-analysis
of global longitudinal strain and ejection fraction. Heart.
2014;100:1673-80. 
                                          [Oncology Reviews 2021; 15:510]                                                            [page 33]
                                                                                                                                Review
No
n-c
om
me
rci
al 
us
e o
nly
